Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say

  • 📰 CNBC
  • ⏱ Reading Time:
  • 52 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 72%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

A complicated legal fight over abortion pill mifepristone could reduce innovation in the biopharma industry, companies and experts in law and economics said.

The Justice Department will seek emergency intervention from the U.S. Supreme Court, it said Thursday.

That outcome would bring uncertainty to a regulatory framework that drugmakers rely on during the expensive and lengthy process of developing medications, they told CNBC. He said that kind of legal fight could have an effect similar to that of a drug's patent expiring, which reduces the medication's time on the market and typicallyA potential legal challenge is a "risk that effectively reduces the economic incentives of bringing drugs to the market," Lakdawalla said. He said it could cause companies and investors to funnel less money into drug research and development.

It takes at least 10 years on average for a new drug to reach the marketplace after its initial discovery, according to, the primary lobbying arm of the pharmaceutical industry. Clinical trials alone take six to seven years on average. Hastings was among the biopharma executives who first issued the open letter. He said the industry is "going to have trouble" if Kacsmaryk's ruling is ultimately upheld.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 12. in BR

Brasil Últimas Notícias, Brasil Manchetes